Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.

Summary

Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.

Timeline

Start

2003-02

Primary completion

—

Completion

2006-01

Publications

• Results Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yeni P, Morineau P, Delfraissy JF, Chene G, Levy Y; ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007 Nov 30;21(18):2425-34. doi: 10.1097/QAD.0b013e3282887e91.
• Rabian C, Tschope I, Lesprit P, Katlama C, Molina JM, Meynard JL, Delfraissy JF, Chene G, Levy Y; ANRS 114 Pneumovac Study Group. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. Clin Infect Dis. 2010 Apr 15;50(8):1174-83. doi: 10.1086/651418.

Drugs

Indications